Business News • MarketWire • Stellar Biotechnologies Receives US$ 288,000 Payment |
Stellar Biotechnologies Receives US$ 288,000 Payment |
|
|
Stellar Biotechnologies Receives US$ 288,000 Payment
PORT HUENEME, CA--(Marketwire - September 30, 2010) - (TSX-V: KLH) (PINKSHEETS: SBOTF) -- Stellar Biotechnologies, Inc. received payment of US$ 288,000 for a filled order of Stellar KLH/SUBUNIT from French biotechnology and active immunotherapy technology-platform company, Neovacs SA, for its Phase IIa human trials with its KLH-based vaccine for rheumatoid arthritis (RA) which has moved to a higher dose group, and its upcoming Phase I trial for Lupus. Neovacs has announced it expects data in second quarter 2011.
View More : http://www.marketwire.com/mw/release.do?id=1327510&sourceType=3
|
|
|